News stories about Blueprint Medicines Corporation (NASDAQ:BPMC) have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blueprint Medicines Corporation earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.2175972248202 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Blueprint Medicines Corporation (NASDAQ BPMC) traded down 1.81% on Friday, reaching $46.11. 304,564 shares of the company’s stock traded hands. Blueprint Medicines Corporation has a 12 month low of $23.71 and a 12 month high of $56.81. The firm’s market cap is $1.80 billion. The firm’s 50-day moving average is $51.90 and its 200 day moving average is $42.60.

Blueprint Medicines Corporation (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.11. The company had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The business’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same period last year, the company posted ($0.70) EPS. Equities analysts predict that Blueprint Medicines Corporation will post ($3.59) EPS for the current year.

Several research firms have issued reports on BPMC. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. Zacks Investment Research lowered shares of Blueprint Medicines Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. BidaskClub upgraded shares of Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Wedbush restated an “outperform” rating and set a $55.00 price target on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. Finally, Jefferies Group LLC raised their price target on shares of Blueprint Medicines Corporation from $42.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, May 4th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $47.90.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-blueprint-medicines-corporation-nasdaqbpmc-stock-price/1480026.html.

In other news, CEO Jeffrey W. Albers sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $49.62, for a total transaction of $1,488,600.00. Following the completion of the sale, the chief executive officer now owns 18,272 shares of the company’s stock, valued at $906,656.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Lynch sold 32,500 shares of the stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $50.28, for a total value of $1,634,100.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 128,622 shares of company stock valued at $6,484,605. Insiders own 3.40% of the company’s stock.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.